Sanofi disclosed a Phase III failure for tolebrutinib in primary progressive multiple sclerosis (Perseus) and warned the FDA review for another indication will likely miss the targeted PDUFA date. The company said the Perseus study did not meet its primary endpoint and submitted an expanded‑access protocol for ongoing patients. The dual setbacks complicate Sanofi’s launch expectations and timing for a drug they acquired for blockbuster potential.